Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
P/E ratio for Nektar Therapeutics (NKTR)
P/E ratio as of 2023: -0.39
According to Nektar Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.39. At the end of 2022 the company had a P/E ratio of -1.15.
P/E ratio history for Nektar Therapeutics from 1994 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.39 |
| 2022 | -1.15 |
| 2021 | -4.73 |
| 2020 | -6.83 |
| 2019 | -8.57 |
| 2018 | 8.69 |
| 2017 | -96.32 |
| 2016 | -11.15 |
| 2015 | -27.49 |
| 2014 | -36.47 |
| 2013 | -8.11 |
| 2012 | -4.95 |
| 2011 | -4.72 |
| 2010 | -31.87 |
| 2009 | -8.43 |
| 2008 | -14.96 |
| 2007 | -18.82 |
| 2006 | -8.82 |
| 2005 | -7.64 |
| 2004 | -15.59 |
| 2003 | -16.27 |
| 2002 | -4.16 |
| 2001 | -3.94 |
| 2000 | -21.77 |
| 1999 | -18.83 |
| 1998 | -28.26 |
| 1997 | -35.92 |
| 1996 | -17.18 |
| 1995 | -13.15 |
| 1994 | -10.77 |